Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAS1 | P04201 | 1/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 14/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24637539 | 0.93 | MAS1 (0.87) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL18768098 | 0.93 | MAS1 (0.87) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637534 | 0.93 | MAS1 (0.86) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637550 | 0.92 | MAS1 (0.85) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24019101 | 0.92 | MAS1 (0.85) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637561 | 0.91 | MAS1 (0.84) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637566 | 0.91 | MAS1 (0.83) | MAS1AGTR2 | |
| SCHEMBL24637565 | 0.90 | MAS1 (0.81) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637522 | 0.88 | MAS1 (0.79) | MAS1AGTR2MEN1GMNNUSP2 | |
| SCHEMBL24637535 | 0.86 | MAS1 (0.76) | MAS1AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| CN-119818488-A | Application of specific excitation of Mas receptor in medicine for preventing and treating liver ischemia reperfusion injury | 上海市同济医院 | 2025-04-15 | — | — | CN | claimed |
| US-20250082716-A1 | REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-03-13 | — | — | US | claimed |
| CN-118680926-B | Application of MAS receptor agonist in preparation of medicine for preventing or treating polycystic ovary syndrome | 北京市糖尿病研究所(北京市糖尿病防治办公室) | 2024-12-20 | — | — | CN | claimed |
| CN-118680926-A | Application of MAS receptor agonist in preparation of medicine for preventing or treating polycystic ovary syndrome | 北京市糖尿病研究所(北京市糖尿病防治办公室) | 2024-09-24 | — | — | CN | claimed |
| WO-2024054198-A1 | REPRESSED ANG 1-7 IN COVID-19 IS INVERSELY ASSOCIATED WITH INFLAMMATION AND COAGULATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-03-14 | — | — | WO | claimed |
| CN-114832109-B | Application of specific excited Mas receptor in preventing and treating acetaminophen induced drug-induced liver injury | 上海市同济医院 | 2023-04-18 | — | — | CN | claimed |
| CN-114832109-A | Application of specific excited Mas receptor in preventing and treating acetaminophen induced drug-induced liver injury | 上海市同济医院 | 2022-08-02 | — | — | CN | claimed |
| CN-122036683-A | Non-peptide MAS agonist and preparation method and application thereof | 四川大学 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| CN-121534051-A | Application of AVE0991 in preparation of novel target medicine for preventing and/or treating hypertensive renal injury | 华北理工大学 | 2026-02-17 | — | — | CN | disclosed |
| CN-121534051-A | Application of AVE0991 in preparation of novel target medicine for preventing and/or treating hypertensive renal injury | 华北理工大学 | 2026-02-17 | — | — | CN | disclosed |
| US-12551495-B2 | Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection | BIOPHYTIS (FR) | 2026-02-17 | — | — | US | disclosed |
| CN-119876097-A | Application of angiotensin converting enzyme 2 as target spot of medicine for treating traumatic brain injury | 济宁市第一人民医院(济宁市医学科学研究院) | 2025-04-25 | — | — | CN | disclosed |
| WO-2013158959-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE | TARIX PHARMACEUTICALS LTD. (US) | 2013-10-24 | — | — | WO | disclosed |
| US-8557958-B1 | Compositions and methods for treatment of diabetes | TARIX PHARMACEUTICALS LTD. (US) | 2013-10-15 | — | — | US | disclosed |
| US-20130237478-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE | TARIX PHARMACEUTICALS LTD. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130210726-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE | TARIX PHARMACEUTICALS LTD. (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2013119870-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE | TARIX PHARMACEUTICALS LTD. (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013090833-A1 | ANGIOTENSINS FOR TREATMENT OF FIBROSIS | TARIX PHARMACEUTICALS LTD. (US) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210726-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE | AGTR2, ACE2, ACE | MAS1 522/4885AGTR2 1/4885MEN1 4052/4885 |
| US-20130237478-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF PERIPHERAL VASCULAR DISEASE | AGTR2, ACE2, ACE | MAS1 522/4885AGTR2 1/4885MEN1 4052/4885 |
| US-12551495-B2 | Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection | ACE2, TMPRSS2, ACE | MAS1 1625/4885AGTR2 52/4885MEN1 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.